U.S. markets open in 9 hours 29 minutes

Edited Transcript of MDT earnings conference call or presentation 18-Feb-20 1:00pm GMT

Q3 2020 Medtronic PLC Earnings Call

Dublin Mar 5, 2020 (Thomson StreetEvents) -- Edited Transcript of Medtronic PLC earnings conference call or presentation Tuesday, February 18, 2020 at 1:00:00pm GMT

TEXT version of Transcript

================================================================================

Corporate Participants

================================================================================

* Brett A. Wall

Medtronic plc - Executive VP & Group President of Restorative Therapies Group

* Geoffrey Straub Martha

Medtronic plc - President & Director

* Karen L. Parkhill

Medtronic plc - Executive VP & CFO

* Michael J. Coyle

Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group

* Omar S. Ishrak

Medtronic plc - Chairman & CEO

* Robert John White

Medtronic plc - Executive VP & President of Minimally Invasive Therapies Group

* Ryan Weispfenning

Medtronic plc - VP of IR

* Sean M. Salmon

Medtronic plc - EVP & Group President of Medtronic Diabetes

================================================================================

Conference Call Participants

================================================================================

* Christopher Thomas Pasquale

Guggenheim Securities, LLC, Research Division - Director and Senior Analyst

* David Ryan Lewis

Morgan Stanley, Research Division - MD

* Joshua Thomas Jennings

Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

* Kaila Paige Krum

SunTrust Robinson Humphrey, Inc., Research Division - Research Analyst

* Kristen Marie Stewart

Barclays Bank PLC, Research Division - Research Analyst

* Lawrence H. Biegelsen

Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst

* Matthew Charles Taylor

UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

* Matthew Oliver O'Brien

Piper Sandler & Co., Research Division - MD and Senior Research Analyst

* Matthew Stephan Miksic

Crédit Suisse AG, Research Division - Senior Research Analyst

* Philip Chickering

Deutsche Bank AG, Research Division - Research Analyst

* Robert Adam Hopkins

BofA Merrill Lynch, Research Division - MD of Equity Research

* Robert Justin Marcus

JP Morgan Chase & Co, Research Division - Analyst

* Vijay Muniyappa Kumar

Evercore ISI Institutional Equities, Research Division - MD

================================================================================

Presentation

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

Ladies and gentlemen, thank you for standing by, and welcome to the Medtronic third quarter earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to Ryan Weispfenning, Vice President, Head of Investor Relations. Please go ahead, sir.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [2]

--------------------------------------------------------------------------------

Thank you. Good morning, and welcome to Medtronic's Fiscal Year 2020 Third Quarter Conference Call and Webcast. During the next hour, Omar Ishrak, Medtronic Chairman and Chief Executive Officer; Karen Parkhill, Medtronic Chief Financial Officer; and Geoff Martha, Medtronic President, will provide comments on the results of our third quarter, which ended on January 24, 2020. After our prepared remarks, we'll be happy to take your questions.

First, a few logistical comments. Earlier this morning, we issued a press release containing our financial statements and the revenue by division summary. We also issued an earnings presentation that provides additional details on our performance and outlook.

During today's earnings call, many of the statements made may be considered forward-looking statements, and actual results may differ materially from those projected in any forward-looking statement. Additional information concerning factors that could cause actual results to differ is contained in our periodic reports and other filings that we make with the SEC, and we do not undertake to update any forward-looking statement.

For this call, unless we say otherwise, rates and ranges are given on a constant-currency basis, which compares to the third quarter of fiscal year 2019 after adjusting for foreign currency. References to organic revenue growth exclude the impact of our Titan Spine acquisition and currency. Reconciliations of all non-GAAP financial measures can be found in the attachment to our earnings press release or on our website at investorrelations.medtronic.com. Finally, our EPS guidance does not include any charges or gains that would be reported as non-GAAP adjustments to earnings during the fiscal year.

With that, I'm now pleased to turn the call over to Medtronic Chairman and Chief Executive Officer, Omar Ishrak. Omar?

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [3]

--------------------------------------------------------------------------------

Thank you, Ryan, and thank you to everyone for joining us. This morning, we reported results for the third fiscal quarter. Revenue growth was light this quarter, reflecting a series of largely transient issues, which I'll walk you through in a minute.

The good news, however, is that this was more than offset by 90 basis points of operating margin expansion, well ahead of our expectations, resulting in strong EPS and free cash flow growth, both ahead of plan. Importantly, despite the top line shortfall this quarter, our Q4 outlook is unchanged as we expect significant revenue growth acceleration excluding any impact from the coronavirus.

Q3 revenue grew 2.9% constant currency and 2.6% organic. Revenue growth fell short of our expectations, driven in part by customers curbing their purchasing ahead of our new product launches, principally in CVG and RTG. In MITG, we upgraded the group's ERP system in the U.S. and Canada to our company-wide system, resulting in a temporary slowdown in our ability to supply customers, which in some cases, resulted in lost procedures and lasted longer in the quarter than we anticipated. That upgrade is now complete, and as of early this quarter, we're in the process of returning to full supply.

All of these items led to our quarterly revenue underperformance. We weren't able to offset these issues given that many of them emerged late in the quarter. I'm not happy with this top line performance, and we are focused on quickly addressing the dynamics that led to this result. Geoff will provide a little more color on this later in the call.

Looking down the P&L. We drove significant operating leverage despite the softer top line. Our adjusted operating margin expanded 90 basis points as we continued to see the benefits of our enterprise excellence initiatives, particularly on the SG&A line. We also had strong financial leverage, driven in part by the debt refinancing that we completed earlier this fiscal year. This resulted in an adjusted EPS of $1.44, which was $0.06 above the midpoint of our guidance and up 11.6% year-over-year.

Let's take a look now at the drivers for our group performances, starting with our Restorative Therapies Group which grew 3.6% organic this quarter. RTG's performance was affected by customer buying patterns in BMP and the continued market slowdown and slight share loss in Pain Stim ahead of our DTM therapy launch. On an organic basis, our overall Spine division was flat this quarter, reflecting customer drawdown of Infuse inventory.

Despite this, our Core Spine business grew 2%, both globally and in the U.S. In addition, when you include sales of enabling technologies sold by our Brain Therapies division, which is how our competitors report, Core Spine grew 5% organically both globally and in the U.S., well above market.

Our Surgical Synergy strategy is resulting in increased sales of our Core Spine implants, driven by surgeons' use of our capital equipment, in particular our Mazor robot. It is also benefiting our Brain Therapies division, which sells the capital equipment used in spine surgery. Brain Therapies delivered another above-market quarter of 9.2% growth. In Neurosurgery, which grew low double digits, we had strong growth in Mazor robotics where we are meaningfully outpacing the competition as well as in StealthStation navigation, O-arm imaging and our new Midas Rex MR8 systems.

In Brain Therapies, our market-leading Neurovascular business had another strong quarter with mid-teens growth driven by mid-20s growth in ischemic stroke on strong adoption of our Solitaire X stent retriever, Riptide Aspiration System and React catheters. In pain therapies, the pain Stim market had another sluggish quarter, and we had some slight share loss ahead of the launch of the Stimgenics DTM therapy on our Intellis platform.

We're excited about the response we've received from physicians and the broader SCS community following the acquisition announcement and Stimgenics data presentation last month at NANS as well as on our 9-year battery warranty on Intellis. We continue to be optimistic about the outlook for the Pain Stim market and have begun training physicians on the DTM waveform.

Our Minimally Invasive Therapies Group grew 3.2% organic, including flat results in the U.S. MITG's performance this quarter was affected by the upgrade of its ERP system in the U.S. and Canada, which caused some temporary slowdown in our ability to supply customers with the full breadth of our products and, in some cases, resulted in lost procedures. This was, however, a transient issue. The ERP upgrade is now complete, and the related supply slowdown are behind us as of this month.

Within MITG, our Surgical Innovations division grew 3.6% this quarter, driven by our Advanced Surgical business, particularly in Advanced Energy, which grew in the high single digits on strength in our LigaSure franchise and sales of our Valleylab FT10 energy platform. Respiratory, GI and renal division grew 2.2%, driven by low double-digit growth in our GI solutions business and high single-digit growth in pulse oximetry sensors and advanced parameter sensors.

In our Cardiac and Vascular Group, we grew 1.8% this quarter, which was below our expectations, due in part to customers holding back their purchasing ahead of new product launches in CRHF. We saw high single-digit declines in our High Power business as customers awaited approval of our Cobalt and Crome devices, which have launched this month in Europe and are expected to launch in the U.S. during Q1. In heart failure, although our LVAD business has anniversaried the headwinds we faced over the past year, the business declined in the low single digits and hasn't returned to the growth levels we were expecting.

The other driver of our below expectation CVG performance was our U.S. TAVR business, which grew 13% this quarter, below the market growth rate. While the TAVR market has been rapidly expanding, we currently have fully experienced field support coverage in a little more than 2/3 of the approximately 700 U.S. centers performing TAVR. We began aggressively hiring and training new field personnel months ago. However, our data shows that it's taking longer than expected for our new reps to reach full productivity. We plan to certify an additional 70 field personnel by the end of this fiscal year.

We expect our U.S. TAVR performance to improve relative to the market going forward as our expanded field organization reaches full productivity and we focus the market on the hemodynamic benefits of Evolut PRO+ platform and the launch of our new Confida sheath. Outside the U.S., our TAVR market share grew modestly in Q3.

Our pacing business grew in the high single digits, well above the market, driven by our exclusive Micra leadless pacemaker and AZURE family of conventional pacemakers. We announced the Micra AV approval in the last week of our quarter and are excited about its growth potential as it expands the Micra target population from 15% to 55% of pacemaker patients. While we did not have revenue from Micra AV in the third quarter, we are already seeing strong interest and early adoption of this new technology in the fourth quarter.

In Diabetes, we grew 0.8%, slightly ahead of expectations. Our U.S. business declined in the low double digits, which is anticipated and resulted from competitive challenges while we await our new products. We're seeing strong enrollment in our Next Tech Pathway program, which allows purchasers of the MiniMed 670G to upgrade for free to our next-generation pump when launched. Keep in mind that as a result of this program, we are currently deferring a portion of the revenue for our pump sales, which we will recognize when patients trade in their 670G for the next-generation pump.

In markets outside the United States, which represents just under half of our Diabetes revenue, we had solid mid-teens growth, driven by the continued adoption of the MiniMed 670G. This demand is not only driving strong growth in our installed base. It is also resulting in double-digit growth in recurring revenue from CGM and other consumables.

Now turning to emerging markets, which represented 17% of our revenue. In Q3, we grew emerging markets 14% with contributions from geographies around the globe. China grew 14%, as is Southeast Asia. And Eastern Europe grew 16%, which included 39% growth in Russia. In addition, South Asia grew 13%, as did the Middle East and Africa. And Latin America grew 12%. We continue to drive strong growth in these markets as we optimize the distribution channel and, in certain markets, localize R&D and manufacturing.

Regarding the coronavirus, our top concern is the health and well-being of our employees in China and across the globe. We have activated response teams in China, the Asia Pacific region and globally, and we remain vigilant in monitoring the virus and taking action as necessary. All of our manufacturing operations are up and running in China. We're committed to helping the Chinese government and Chinese physicians address this crisis.

As the Chinese health care system is focused on containing the spread of the virus, hospitals in China have experienced a slowing of medical device procedure rates, and we are seeing procedure delays. We do expect this to have a negative impact on our fourth quarter financial results. But given the fluidity of this situation, the duration and magnitude of the impact are difficult to quantify at this time.

Now turning to our product pipeline. As we look forward, we're excited about what lies ahead as the investments we've made in our product pipeline begin to pay off by accelerating our revenue growth and creating value for our shareholders. We have recently received approval or launched a number of new products that we expect to contribute to our growth going forward.

I mentioned earlier the U.S. approval of our Micra AV pacemaker and the launch that is now underway. We also received U.S. approval for our IN. PACT Admiral AV fistula indication, which expands the market potential of our drug-coated balloons. We received U.S. approval and are launching our Stealth Autoguide cranial robotic system. In Europe, we recently received CE mark approval for our Cobalt and Crome portfolio of BlueSync-enabled high-power devices, our InterStim Micro rechargeable implantable sacral neuromodulation device and InterStim SureScan MRI leads as well as our Percept PC DBS device with BrainSense technology.

And over the next few quarters, we expect approval and launch of a number of additional new products. We expect U.S. approval of the Cobalt and Crome high-power devices, Reveal LINQ 2.0 insertable cardiac monitor, InterStim Micro and InterStim SureScan MRI leads and our Percept PC DBS device. We're also expecting European launch of the MiniMed 780G and our DiamondTemp ablation catheter.

Regarding our MiniMed 780G in the U.S., we intend to file our adult clinical data with the FDA in March, which will push expected approval beyond the fiscal year-end. In Pain Stim, we unveiled DTM spinal cord stim last month at the NANS conference and are now training our field force on this novel waveform, with an expected limited launch in Q4 and full launch in Q1.

In MITG, we continue to make progress in our soft tissue robotics program. Last week, we announced the acquisition of Digital Surgery, a pioneer in artificial intelligence and analytics for surgery. They lead the industry with their unique Touch Surgery ecosystem of products, including AI that identify surgical steps and instrumentation. These products can be leveraged to provide insight into the procedure time, cost and process to improve surgical care. We're excited about utilizing the strength and capability of Digital Surgery to advance our minimally invasive and robotic surgery platforms.

We also have a number of important upcoming data presentations, starting with use case data under extreme conditions for our advanced hybrid closed-loop algorithm at ATTD later this week. Next month, ACC will be a big conference for us. Data from our OFF-MED renal denervation pivotal trial will be presented as well as data for both low-risk bicuspid and leaflet immobility for our TAVR program. Also, we will share risk stratification data for our TYRX anti-infection product. And finally, in June, at ADA, we expect to present the U.S. pivotal data for our MiniMed 780G advanced hybrid closed-loop system.

This is just some of the near-term highlights from our pipeline. Importantly, we're continuing to invest in building out a robust long-term pipeline of continuous innovation, invention and disruption.

I mentioned earlier that we expect significant acceleration in our fourth quarter revenue growth, driven in part by our pipeline and excluding the impact of the coronavirus. And as we look to FY '21, we expect our top line momentum to continue as we get the increasing benefit of the FY '20 product launches as well as the products slated to launch next fiscal year.

With that, let me now ask Karen to take you through a discussion of our third quarter financials and forward outlook. Karen?

--------------------------------------------------------------------------------

Karen L. Parkhill, Medtronic plc - Executive VP & CFO [4]

--------------------------------------------------------------------------------

Thank you. As Omar mentioned, we delivered third quarter organic revenue growth of 2.6%, and adjusted EPS was $1.44, growing 11.6%. We ultimately came in $0.06 above the midpoint of our guidance and would attribute $0.02 to better-than-expected foreign exchange and $0.04 to operational outperformance, including tax.

Our adjusted gross margin was 69.7%, down year-over-year due in part to increased China tariffs. We more than offset that decline with strong operating leverage as we continue to implement and drive efficiencies and improvements across the company while, at the same time, making investments ahead of upcoming product launches. This led to an adjusted operating margin improvement of 90 basis points or 70 basis points excluding the impact of currency.

Below the operating profit line, our adjusted interest expense declined 36%, driven by our successful debt issuance and tender transactions that we completed last spring and summer. Our adjusted nominal tax rate was 13.6%, lower than we expected, due to increased deductions from the exercise of employee stock options and benefit from finalizing taxes owed on certain returns.

As you know, generating strong free cash flow remains a priority across the company, and you are seeing this focus come through in our results. Third quarter free cash flow was $2.1 billion, up 21% from last year. And year-to-date, free cash flow was $4.9 billion, representing a conversion ratio of 90%, well above our full year target of 80%-plus.

We remain committed to disciplined capital deployment, balancing investment in R&D and tuck-in acquisitions to drive future growth while returning a minimum of 50% of our annual free cash flow to our shareholders, and year-to-date, we've returned $2.8 billion or 57% of the cash we generated, resulting in a total shareholder payout of 51% on adjusted net earnings.

Now turning to guidance. For the fourth quarter, we are comfortable with current Street consensus on organic revenue growth and EPS prior to any impact from the coronavirus. We expect overall organic top line growth of approximately 4.5%. By group, we expect CVG to grow 4.25% to 4.5%; MITG, 6.25% to 6.5%; RTG, approximately 4% organic; and Diabetes to be flat to down low single digits. And based on recent rates, currency would have a negative impact of 80 to 140 basis points.

On margins, we continue to expect our full year operating margin to expand by roughly 40 basis points on a constant-currency basis, driven by our enterprise excellence initiatives. For the fourth quarter, we expect our operating margin to be up slightly, including the impact of currency, or roughly flat on a constant-currency basis as we invest to support current and upcoming product launches.

Below the operating line, we expect our fourth quarter interest expense to be approximately $160 million to $165 million and our fourth quarter adjusted nominal tax rate to be around 16%, which would put our annual rate at approximately 15%, lower than we originally expected and reflecting the benefits we have had so far this year. We are raising our fiscal year '20 EPS guidance to a range of $5.63 to $5.65, up from $5.57 to $5.63 and reflecting our third quarter bottom line outperformance. For the fourth quarter, we expect $1.62 to $1.64.

As mentioned upfront, all of the guidance I just gave excludes the impact of the coronavirus. Because the situation is so fluid, it is difficult to truly quantify the impact just a few weeks into our quarter. And for that reason, we plan to provide an update for you later this quarter. Finally, I would like to note that we plan to hold our Biennial Institutional Investor and Analyst Day on Tuesday, June 2 in New York City.

Back to you, Omar.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [5]

--------------------------------------------------------------------------------

Thanks, Karen. I'd now like Geoff to make some remarks on the quarter and the outlook. Geoff?

--------------------------------------------------------------------------------

Geoffrey Straub Martha, Medtronic plc - President & Director [6]

--------------------------------------------------------------------------------

Thank you, Omar. There are a number of positive things from the quarter that I want to highlight, but first, I'd like to address our top line performance.

Even though much of it was transient, we did not perform at the level we were expecting, and the drivers surfaced at the end of the quarter. We just can't have surprises like this, for us nor for you. And we are making changes. At our upcoming Investor Day in June, I'm going to walk you through what innovation-driven growth means for Medtronic and the comprehensive set of initiatives to take full advantage of the pipeline. These initiatives are meant to ensure we see the acceleration of our revenue from the pipeline and to improve our predictability.

On that note, I want to discuss an aspect of our plan to address the surprise we saw this quarter. One issue is the weighting of our revenue to the final month of the quarter, which leaves us susceptible to surprises late in the game, like what happened this quarter. Too often, our largest orders come in at the end of the month. This dynamic makes the business challenging to manage, it stresses our operations, and it really makes it difficult to mitigate headwinds that pop up within the quarter. So to fix this, we will change our current operating mechanisms, certain internal metrics and some incentives as well.

And I want to flag the opportunity coming up with our extra week in Q1. The impact of the changes that I just mentioned likely won't be contained in a given quarter, so I'd like to use a good portion of the benefit that we would get from the extra week in Q1 to launch these initiatives. So when we guide to the first quarter, we will give you guidance on an underlying basis excluding the benefit of the extra week, and we'll give you an estimate of the benefit of the extra week net of these changes. Like I said, we plan to discuss these and other changes during our Investor Day. But I want to assure you one thing, that I'm on this and we are taking the appropriate actions to improve consistency and avoid future surprises.

Now before I close and we get to Q&A, I've got to highlight a number of good things that occurred this quarter, accomplishments that I believe can't get lost in this quarter's narrative. First, we drove a better operating margin despite the light top line and free cash flow was outstanding. These are 2 things that we've been working on for a long time. Over the past couple of years, we've taken action on both of these areas, and we feel really good about the operating rigor and the culture we put in place to drive the bottom line and improve cash flow.

Also, emerging markets growth continues to be strong for us. They represented 17% of our revenue and, once again, grew strong double digits, 14% this quarter. We think of emerging markets actually as an independent growth vector for the company, and we have to acknowledge the progress with our pipeline. We are starting to see approvals and launches come through for important and innovative products, and there's more to come. Yes, the slow purchasing ahead of these launches hurt us in some businesses this quarter, but this is going to turn. Customers are really excited about our new offerings.

I'd like to end by saying that the underlying fundamentals of the business are strong. We have a full pipeline that will accelerate our revenue growth and take share not just next quarter but next year and beyond. We're very excited about the future of the company, the new technology that we're bringing to market, the impact this will have on patients and physicians and the value we're going to bring and generate for our shareholders.

All right. Back to you, Omar.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [7]

--------------------------------------------------------------------------------

Thanks, Geoff. I couldn't agree more with the approach that we are taking, and I'm just as excited about our outlook going forward. Before we start Q&A, I'd like to briefly note that we currently anticipate holding our Q4 earnings call, which will be my last earnings call, on Thursday, May 21.

Let's now move on to Q&A. In addition to Karen, Geoff and me, our 4 group presidents: Mike Coyle, Bob White, Brett Wall and Sean Salmon, are also here to answer your questions. (Operator Instructions) If you have additional questions, please contact Ryan and our Investor Relations team after the call.

Operator, first question please.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

Your first question comes from the line of Bob Hopkins with Bank of America.

--------------------------------------------------------------------------------

Robert Adam Hopkins, BofA Merrill Lynch, Research Division - MD of Equity Research [2]

--------------------------------------------------------------------------------

Just I'll state both questions upfront to make it easy. First, I was wondering, in CVG, if we could drill down a little bit on ICDs given the weakness in the quarter. And I asked because Boston Scientific also saw weakness in the quarter in their high-power ICD business, and the timing of your new launches shouldn't really be a surprise. So I guess my first question is how can you have confidence that this isn't just a slower market? So that's question #1.

And then the thing I'd also love a quick comment on is -- I realize it's too early for formal fiscal 2021 guidance, but you guys have talked a lot about accelerating growth in fiscal 2021. So are you still comfortable accelerating off of that 4.5% that we'll see hopefully in the fourth quarter on a same selling day basis?

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [3]

--------------------------------------------------------------------------------

Thanks, Bob. Mike Coyle is the right person to address the ICD questions. Go ahead, Mike.

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [4]

--------------------------------------------------------------------------------

Yes, Bob. We're not seeing anything that would cause us to have a concern that the overall market for ICDs is somehow slowing significantly. Most of the challenges that we have on ICDs remain the issue associated with the replacement cycle and the fact that we were seeing essentially mid-teens declines in year-over-year comparisons on replacement. As I've mentioned before, that actually gets better as we get through the year and into next year, especially in the CRT-D area, and that is going to help us in terms of acceleration in the ICD side.

But the other point -- and you pointed out the surprise to us in terms of weakness in the number for the quarter. It was really in EMEA, in Europe and Middle East and Africa. That was where, essentially, we believe customers were holding off given the imminent launch of our Cobalt/Crome product families, which now have launched into the market. And those products will be coming to the United States during the first quarter.

The other thing that depressed the overall performance relative to where we thought we would be during the quarter is the fact that the TYRX anti-infective envelopes get captured under the ICD numbers when we report externally. And I think -- you may recall, last quarter, we had a fairly major quality-driven back order situation that we expected would be resolved completely during the course of Q3. We actually lost a number of -- lots of product -- manufacturing lots of product early in the quarter, which now has stabilized. In fact, through the second half, we're completely out of any kind of constraints on supply.

So we expect that will flow through into the numbers in Q4 and obviously into next year, especially as we have new data that we'll be presenting at ACC on risk stratification for TYRX. So we think all of those things are going to help us accelerate the ICD market, not only in Q4 but into next year.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [5]

--------------------------------------------------------------------------------

Okay. Thanks, Mike. I think, Karen, you're the best person to take the question about '21.

--------------------------------------------------------------------------------

Karen L. Parkhill, Medtronic plc - Executive VP & CFO [6]

--------------------------------------------------------------------------------

Yes. Thanks for the question on '21, Bob. Yes, we're really excited about our pipeline and what it has to offer for FY '21. I'd love to talk a lot about it, but we're close to finalizing our plan so we'll give the official guidance on our Q4 call, as you know. That said, I would think about accelerating growth for next year off of a full year basis as opposed to off of a sequential basis. And we're very confident in our growth acceleration of FY '21 over FY '20.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [7]

--------------------------------------------------------------------------------

Okay. Thanks, Bob.

--------------------------------------------------------------------------------

Operator [8]

--------------------------------------------------------------------------------

Your next question comes from the line of David Lewis with Morgan Stanley.

--------------------------------------------------------------------------------

David Ryan Lewis, Morgan Stanley, Research Division - MD [9]

--------------------------------------------------------------------------------

Just maybe just one question for me here. Karen, just to confirm from your last question, is the right way to think about fiscal '20 -- I'm assuming a sort of 3.5% to 4%. But my one question, I'll keep it to one, is just thinking about 4Q guidance. I appreciate it's in line with consensus, but when I think about Omar and Geoff's comments about RTG and CVG, it seems like the 3Q dynamic is getting better into the fourth. Should the fourth quarter be stronger as we see some of this catch-up revenue? So can you just help us quantify the third quarter issues and offer some clarity of what fourth quarter implies in terms of recovery and drivers of acceleration?

--------------------------------------------------------------------------------

Karen L. Parkhill, Medtronic plc - Executive VP & CFO [10]

--------------------------------------------------------------------------------

Okay. So let me take the beginning of it, and then I'll let my colleagues jump in, too. So in terms of FY '20, David, our fourth quarter guidance would imply FY '20 growth of 3.6%, 3.7%-ish. And then on fourth quarter, clearly, because of the transient issues in the third quarter, we expect some of that to come back. If you look at MITG and the ERP issues that we've talked about, we fully expect that to come back. And that's one of the reasons that we've guided MITG to above trend for the quarter. But we have lost some procedures, and those won't come back.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [11]

--------------------------------------------------------------------------------

Yes. I think -- I don't know if I can add anything to that. Really, the procedure losses in a business like MITG where the procedures happen, that just isn't going to come back. We'll recover fully. I think in other areas like in the MCS business, or LVAD business, that was share loss. And there is pressure there, and our growth is probably going to be lower than we were originally anticipating.

So in balance, we felt that holding the Q4 sort of previous guidance was the appropriate thing to do at this stage. We're obviously doing everything we can to maximize that number.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [12]

--------------------------------------------------------------------------------

Okay. Thank you, David.

--------------------------------------------------------------------------------

Operator [13]

--------------------------------------------------------------------------------

Your next question comes from the line of Robbie Marcus with JPMorgan.

--------------------------------------------------------------------------------

Robert Justin Marcus, JP Morgan Chase & Co, Research Division - Analyst [14]

--------------------------------------------------------------------------------

Maybe if we could shift to some of the product lines and specifically TAVR here, 13% worldwide growth, came in a lot lower than The Street was expecting. You had the first full quarter of the low-risk launch in the U.S. Your competitor did a lot better than this. Maybe talk to exactly what happened in the quarter, the dynamics in the U.S. and how you expect this continue throughout fourth quarter and '21.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [15]

--------------------------------------------------------------------------------

Mike, do you want to take that?

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [16]

--------------------------------------------------------------------------------

Yes, Robbie. Obviously, we were very disappointed with the performance in the U.S. If you look outside the U.S., we -- the implant growth rates were in the high teens and pretty much in line with the overall market, actually a little better than the overall market because of the Japan influence, but in the United States, obviously well below market with implant rates in the mid-teens, whereas we would estimate the market in the quarter probably grew on the order of the low 30s. As we dug into that, we obviously headed into the holidays actually feeling pretty good that we were looking at implant rates in the low 20s. Obviously, in retrospect, that turns out to be lower than the market.

But as we headed into the end of the year and into January, we saw a pretty meaningful decline in overall growth rates for implants, and we dug deeply into that to figure out which accounts and where we were having the issues. And basically, I think learning from that analysis was that it takes longer than we thought to have our reps become fully competitive in this market. It's probably a 9- to 12-month training exercise, which, in retrospect, we probably should have ramped up in advance of this several quarters earlier than we did.

The good news is that as we look at the hiring that we did do, this quarter, we expect to bring on 70 new sales reps and support personnel, which is going to help us go from -- given the 700 accounts that are selling ICD or selling -- that are servicing this market, we probably have seasoned sales reps, that is those who have a year or more experience in about 2/3 of those accounts. By the time we exit with these new certifications, we would expect to be closer to 80% in terms of supporting that. And we're also accelerating new hiring based on driving support for our next fiscal year.

So we think those just catch up in terms of training and deployment. Plus we're pushing much more closed interval management of the reps that are out there to make sure that we're staying on top of developments in these accounts. We think that, coupled with, obviously, our new product launch around Evolut PRO+; the launch of the Confida sheath, which really improves the performance of our overall device systems; and then new data that will be coming out here at ACC around both bicuspid and leaflet immobility, should basically give us an opportunity to accelerate from where we were in Q4 -- or in Q3.

And basically, looking at just the daily sales rates here as we've headed into the new quarter with this new focus on rep productivity, we are seeing some acceleration from those numbers that you see in terms of the mid-teens implant rates. And so I'm confident we're going to see acceleration. Whether we'll get all the way back to market, given that we have 2 competitors who are driving share in those accounts, it may take more than a quarter to do that. But on the other hand, I do expect to see acceleration during the quarter.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [17]

--------------------------------------------------------------------------------

Okay. Thank you, Robbie.

--------------------------------------------------------------------------------

Operator [18]

--------------------------------------------------------------------------------

Your next question comes from the line of Vijay Kumar with Evercore.

--------------------------------------------------------------------------------

Vijay Muniyappa Kumar, Evercore ISI Institutional Equities, Research Division - MD [19]

--------------------------------------------------------------------------------

I had 2 quick ones. One, on Surgical Robotics, I think you mentioned some software updates, just on time line there. MITG, you have sequential acceleration. Is there anything baked on the robotic side there?

And second, on margins. I appreciate the comments on FX hedge gains. When you look at next year, I think Geoff made some comments on changing incentives. So maybe just talk about margins for next year. Are we still looking at constant currency in that 40 to 50 basis points of expansion?

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [20]

--------------------------------------------------------------------------------

Okay. Let me -- Bob will probably answer this, but I'll just say off the bat that robotics is not in our financial numbers yet. And the overall program is more or less on track, so...

--------------------------------------------------------------------------------

Robert John White, Medtronic plc - Executive VP & President of Minimally Invasive Therapies Group [21]

--------------------------------------------------------------------------------

Yes, that's right, Omar. Thanks, Vijay, for the question. To reiterate, first off, no update from what we talked about at JPMorgan relative to the program. So it's just good news. And then the sequential acceleration of MITG's business is really all about us coming out of the ERP implementation now that we've got that back on track and the system is running smooth. So hopefully, that does it for you, Vijay.

--------------------------------------------------------------------------------

Vijay Muniyappa Kumar, Evercore ISI Institutional Equities, Research Division - MD [22]

--------------------------------------------------------------------------------

Yes. And then on the margins, guys?

--------------------------------------------------------------------------------

Karen L. Parkhill, Medtronic plc - Executive VP & CFO [23]

--------------------------------------------------------------------------------

Yes. Thanks, Vijay. On margins, for next year, we're going to continue to look at margin expansion as we drive bottom line growth above top line growth every year. At this stage, we haven't changed our long-range guidance of 40 basis points constant-currency margin expansion so you can assume that at this stage.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [24]

--------------------------------------------------------------------------------

I can tell you, Vijay, there's a focus in the organization around that. We've worked very hard to get an accountability around that, and we're going to -- that's going to stay. We just need to fix our top line growth back to where it deserves to be based on our product pipeline.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [25]

--------------------------------------------------------------------------------

Okay. Thanks, Vijay.

--------------------------------------------------------------------------------

Operator [26]

--------------------------------------------------------------------------------

Your next question comes from the line of Matt Taylor with UBS.

--------------------------------------------------------------------------------

Matthew Charles Taylor, UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices [27]

--------------------------------------------------------------------------------

So the first one I wanted to ask was just on MITG ERP transition. I was wondering if that impacted any of the business lines within MITG more than the others. And are you seeing underlying share loss there or share gains? Can you talk about the underlying trends?

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [28]

--------------------------------------------------------------------------------

Go ahead.

--------------------------------------------------------------------------------

Robert John White, Medtronic plc - Executive VP & President of Minimally Invasive Therapies Group [29]

--------------------------------------------------------------------------------

Yes. Let me take that, Omar. Yes, Matt, thanks for the question. The impact of the ERP transition affected all of the MIT product lines as we migrated into the single SAP system for Medtronic. And certainly, we lost some procedures when we weren't able to ship products to customers. So while we think we lost procedures given the middle months of the quarter, we don't believe we necessarily lost significant amounts of share. But certainly, now that we're back on track with the ERP system, we're back to fulfilling those customer requirements.

--------------------------------------------------------------------------------

Matthew Charles Taylor, UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices [30]

--------------------------------------------------------------------------------

And just a follow-up for Mike or the team here. So it sounds like you're seeing a little bit of an improvement in the DCB trends, at least in the U.S. Could you speak to that and whether you think we could see a kind of continued uptick there or a change in the FDA stance at some point during the year?

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [31]

--------------------------------------------------------------------------------

Sure. We are seeing some modest improvement. Obviously, as more datasets come in, they're providing more comfort to physicians and the FDA for that matter, I believe, that the signal that had been observed in those first 3 randomized trials around SFA seem not consistent with the new data coming in. Obviously, one big dataset that we filed and got approval for was the AV fistula indication for DCB, which did not show this mortality signal in the paclitaxel arm. And we expect additional data to be coming out on that topic, including at the ACC, where we think there will be a presentation of a major dataset based on claims analysis.

So that is creating a greater sense of confidence in the physician base that the significant morbidity issues that come with not using these drug-coated balloons and just using PTA balloons are beginning to get attention. And I think what we expect to see is continued improvement as datasets provide that level of comfort. So in this quarter, we did see, on a sort of selling adjusted basis, some sequential growth, which is encouraging in DCB. And we expect, if the data continue to come in as positive as they have, that we'll see that continue.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [32]

--------------------------------------------------------------------------------

Thanks, Matt.

--------------------------------------------------------------------------------

Operator [33]

--------------------------------------------------------------------------------

Your next question comes from the line of Kristen Stewart with Barclays.

--------------------------------------------------------------------------------

Kristen Marie Stewart, Barclays Bank PLC, Research Division - Research Analyst [34]

--------------------------------------------------------------------------------

I just wanted to ask Sean if he could just provide his overall thoughts on Diabetes since he's kind of taken over the role and then if we could just kind of get an update on 780G. It sounds like that is getting pushed a little in the U.S. into next fiscal year. Maybe just some thoughts around the time line there.

--------------------------------------------------------------------------------

Sean M. Salmon, Medtronic plc - EVP & Group President of Medtronic Diabetes [35]

--------------------------------------------------------------------------------

Sure. Thanks, Kristen. So as you know, the Diabetes business certainly has no small challenges to overcome. But I can tell you I'm really very encouraged with how we're seeing some derisking of the pipeline that we have going forward. In particular, that sensor pipeline, I'm convinced that we've figured that out, and it's just a bit of time for us to get the product line flowing there.

The 780G is an important catalyst for us to drive growth, and we expect that to begin. We have filed the CE mark for that device, and we are anticipating, as Omar said, putting the clinical data module in, in the March time frame. That review is going well. We're very interactive with FDA. In fact, we'll be meeting with them later this week. And we'll give more update on exactly what the timing is as we get more information on it.

So, so far, we're happy with what we're seeing both from the algorithms, and you'll see some of that later this week as we stress the algorithm into some challenging conditions that will be announced at ATTD; and the data front, and you'll see the full dataset coming up at the ADA in June. So I've seen a lot of encouraging things. There are things to clean up obviously. We've got to get the new product flow going, and we're confident that we'll be doing that starting soon.

--------------------------------------------------------------------------------

Kristen Marie Stewart, Barclays Bank PLC, Research Division - Research Analyst [36]

--------------------------------------------------------------------------------

And then just your comments around the derisking, particularly around the sensors, can you maybe just expand upon that? Do you think there's an opportunity to bring forward some of the sensor time lines?

--------------------------------------------------------------------------------

Sean M. Salmon, Medtronic plc - EVP & Group President of Medtronic Diabetes [37]

--------------------------------------------------------------------------------

Kristen, I think the first thing is to meet the criteria for iCGM, and I'm confident that we're going to be able to demonstrate that. We'll have more information on that in the coming meeting. But probably at Analyst Day, we'll show you some more of that. It's too early to comment on accelerated timing, but that's certainly the goal, to push as fast as we can into the marketplace.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [38]

--------------------------------------------------------------------------------

Thank you, Kristen.

--------------------------------------------------------------------------------

Operator [39]

--------------------------------------------------------------------------------

Your next question comes from the line of Kaila Krum with SunTrust.

--------------------------------------------------------------------------------

Kaila Paige Krum, SunTrust Robinson Humphrey, Inc., Research Division - Research Analyst [40]

--------------------------------------------------------------------------------

So one quick one to clarify and then a question on the business. So on the coronavirus, I think you may have mentioned this, but again, just to clarify. Will you give full transparency on your China business performance in the fourth quarter?

--------------------------------------------------------------------------------

Karen L. Parkhill, Medtronic plc - Executive VP & CFO [41]

--------------------------------------------------------------------------------

Yes, we will. And we did disclose our growth rates in China already so we will continue to disclose that. We will be transparent about the impact of the coronavirus.

--------------------------------------------------------------------------------

Kaila Paige Krum, SunTrust Robinson Humphrey, Inc., Research Division - Research Analyst [42]

--------------------------------------------------------------------------------

Perfect. And then there's obviously a lot of new product launches coming in the next few quarters. But -- I mean obviously, it can be challenging to predict the timing and the impact of when those new launches contribute. So I'm just curious how you're modeling new product contribution in the fourth quarter as part of that reacceleration in the business.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [43]

--------------------------------------------------------------------------------

Well, there are some that are pretty clear. Things like the Micra AV, which launched last quarter, is now in full steam and moving ahead well, and that one, we're projecting a strong success. There are others, like the -- in the spinal cord stimulation market, we just launched the Stimgenics waveform on the Intellis platform. That's picking up. That's -- we're a little more guarded about that because that's newer, but for sure, that's going to help us in the spinal cord stimulation market.

Things like Cobalt/Crome in Europe, again, we have a history there, and we can project historically what such -- that kind of improvement has caused and we're going to put that into our model. So there's a mix of the level of sort of confidence intervals we have in these projections, some very tight, and Micra being one of the biggest drivers is very tight. The other is a little more unknown but positive nonetheless.

I think that's the best I can do. I don't know, anyone else here, any products I've missed or any comments, you guys?

--------------------------------------------------------------------------------

Brett A. Wall, Medtronic plc - Executive VP & Group President of Restorative Therapies Group [44]

--------------------------------------------------------------------------------

Well, we've recently launched the Micro, which is the new public health product in Europe, which -- we're excited about that and the possibility for that looking to a late spring launch in the United States. And then Percept, which is the new DBS device with BrainSense technology, has just launched in Europe. Similar time frames in the U.S. approval and we're getting good uptake on that. So those are 2 very interesting platforms for us in the neuromodulation space.

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [45]

--------------------------------------------------------------------------------

The other thing I would mention is the DiamondTemp ablation catheter CE mark that we expect during the quarter, which would obviously be even more of a benefit in Q1 of next year. As well as we're just in the early stages of the launch of the AV fistula indication for the IN. PACT Admiral balloon, so those will now get full quarter benefit during Q4.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [46]

--------------------------------------------------------------------------------

I think to your question about how we project this, there's a historical sort of comparison that we can make against similar such launches. And based on that, we make a judgment in our planning, and from that, we derive guidance and our plan going forward. So there's a variety of that, but there is some judgment involved with this.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [47]

--------------------------------------------------------------------------------

Thank you, Kaila.

--------------------------------------------------------------------------------

Operator [48]

--------------------------------------------------------------------------------

Your next question comes from the line of Larry Biegelsen with Wells Fargo.

--------------------------------------------------------------------------------

Lawrence H. Biegelsen, Wells Fargo Securities, LLC, Research Division - Senior Medical Device Equity Research Analyst [49]

--------------------------------------------------------------------------------

Mike, could you please put a finer point on the launch timing of Cobalt and Crome in the U.S. and LINQ 2.0? What quarter are you expecting it?

And Brett, on SNM, what are you seeing -- for sacral neuromodulation, what are you seeing from the new competitor? And what are your expectations for that business before Micro is approved in the U.S. in late spring, which is what I heard you say a minute ago?

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [50]

--------------------------------------------------------------------------------

So Larry, on Cobalt and Crome, we would expect that in the first quarter of next year, probably in the first half of that quarter. And then for LINQ 2.0, we would expect that product also in Q1 but in the second half of the quarter.

--------------------------------------------------------------------------------

Brett A. Wall, Medtronic plc - Executive VP & Group President of Restorative Therapies Group [51]

--------------------------------------------------------------------------------

Yes. And then, Larry, on public health and on the Micro, I think we expect some near-term slowing here with that particular product given the competition. The Micro itself in Europe has been received very well. Just as a reminder, it's about half the size of the competitive device. The recharge experience is significantly better. And with the SureScan leads, it is 1.5 and 3 Tesla full body conditional. So we're very, very excited about that product when it comes to the market in the United States.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [52]

--------------------------------------------------------------------------------

Thank you, Larry.

--------------------------------------------------------------------------------

Operator [53]

--------------------------------------------------------------------------------

Your next question comes from the line of Matt Miksic with Crédit Suisse.

--------------------------------------------------------------------------------

Matthew Stephan Miksic, Crédit Suisse AG, Research Division - Senior Research Analyst [54]

--------------------------------------------------------------------------------

So I just have one on coronavirus and one on sort of the Symplicity Spyral time line and post the data at ACC. So on corona, I understand it's a little bit early to put a finer point on the impact for Q4, but if you could maybe give us some sense of what the major moving parts are. I think we have about $2 billion in China revenue round numbers, an approximately kind of an annual run rate there. Obviously, it's a moving target, but things like -- would an impact in Q4 likely, based on what you know now, sort of come back in early Q -- how transitory is that impact? And then on Spyral, just maybe walk through for us the time line of what happens after OFF-MED and what that looks like as you continue to develop that program.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [55]

--------------------------------------------------------------------------------

Okay. Let me take the coronavirus question first. First of all, we're pretty clear about what our China business is. It's roughly 7% of our global business, so you can do the estimate there. The variables right now -- one variable is that we've got to get our factories up and running so that we can supply different places in the world, including China, and that is actually progressing well. But the main factor driving the number there will be the procedure uptake in China. China was in a complete shutdown mode for the first half of February, and they're just beginning to start. And even now, even in places like Beijing and others, procedures are only just beginning. It's too early to tell how they will ramp up through the rest of the quarter. We know that in Hubei province, for example, obviously, it shut down, but that's only 5% of China. But the rest of China, in places like Beijing and Shanghai, right now, there are procedure delays.

In addition to that, a lot of physicians are being asked to actually go and help with the virus. And so there are many dynamics here that are really difficult to predict now. Once things stabilize, there could well be a ramp back up. And because people need the procedures, they will get them at some point. When that happens is very difficult to predict right now. So that's why we're saying that wait until a little later in the quarter when we have some more data and see how things progress and we'll give you a full update.

So with that, I'm going to ask Mike to take the renal.

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [56]

--------------------------------------------------------------------------------

So our renal denervation, obviously, the first big milestone will be the pivotal trial on the OFF-MED, which will be presented here at ACC. But there is the second trial that is ongoing in parallel, which is the ON MED trial. Unlike the OFF-MED, it has a 6-month efficacy endpoint. So if I were to set expectations for when those data were to become available, I would expect that about a year from now, so about this time next year.

In terms of the FDA interaction, the ON MED -- or the OFF-MED data will be used in a modular submission as we -- along with, obviously, the device-supporting materials. So we think we can get the process with FDA to move forward. We do think we need the OFF-MED -- or excuse me, the ON MED dataset in order to get final approval for the product, and certainly, it will be very important in terms of reimbursement to have those data. So that would be how I would set expectations.

Obviously, I think you know the Spyral product is available in Europe currently. It does have CE mark. So as these datasets become available, customers can evaluate them and decide how they want to use that product.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [57]

--------------------------------------------------------------------------------

Thanks, Matt.

--------------------------------------------------------------------------------

Operator [58]

--------------------------------------------------------------------------------

Your next question comes from the line of Chris Pasquale with Guggenheim.

--------------------------------------------------------------------------------

Christopher Thomas Pasquale, Guggenheim Securities, LLC, Research Division - Director and Senior Analyst [59]

--------------------------------------------------------------------------------

Mike, I just want to circle back on the 4Q CVG growth outlook. It sounds like some of the headwinds there, like LVADs and TAVR, may take at least another quarter to address. I'd imagine that there's potentially some risk that U.S. ICD growth slows ahead of those launches, just like we saw in Europe. So Micra AV should help. There's a couple of other things that go your way, which is the confidence in driving that acceleration in the fourth quarter.

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [60]

--------------------------------------------------------------------------------

Sure. I think as you point out, we have lowered our expectations for the LVAD numbers just based on not seeing the sequential share capture in Q3 that we had seen in Q2 and some competitive indications approvals. But on the other hand, obviously, we got the Micra AV early in terms of we expected that it will be later in the quarter when we were setting guidance last quarter. And the customer response has been strong in terms of interest in the technology.

And as a reminder, this is a product that carries a 3x price uplift relative to a standard dual-chamber system and our indications for use cover all AV block patients. So we expect an opportunity to drive this product meaningfully into the market above what we were thinking a quarter ago when we were giving guidance for Q4.

In addition, although, obviously, the Cobalt and Crome products won't be in the U.S., they will be in Europe. And so unlike last quarter where we really had no meaningful new products and we saw the customers pausing and -- while waiting for new products, now we have a number of new products globally that are obviously going to make a difference for us. And so net-net, we're pretty much holding our expectations for growth where we were a quarter ago despite the moving pieces in this quarter.

--------------------------------------------------------------------------------

Christopher Thomas Pasquale, Guggenheim Securities, LLC, Research Division - Director and Senior Analyst [61]

--------------------------------------------------------------------------------

And does the guidance contemplate a pause in U.S. ICD orders ahead of those launches?

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [62]

--------------------------------------------------------------------------------

Yes, it certainly shows no meaningful acceleration in those numbers, so something along the lines of what we've had. But as I said, we're also seeing some improvement in the replacement cycle generally because of the CRT-D side of things. And the other thing I should mention is, obviously, we will anniversary in March the paclitaxel issue, which was a big step down in the prior year quarter, which gives us just an easier comp to work with as we've seen sequential growth on a selling days basis the last couple of quarters in DCB.

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [63]

--------------------------------------------------------------------------------

And I don't disagree that TYRX, although we won't get to share capture mode this quickly, we'll certainly have sequential growth over the quarter.

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [64]

--------------------------------------------------------------------------------

Absolutely. That -- we were constrained for more than half of last quarter in terms of supply, and now we are essentially unconstrained. And in addition, we are expecting to get labeling expansion to 1-year dating on that product in the United States, which will help us significantly in terms of just the logistics of its growth.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [65]

--------------------------------------------------------------------------------

Thanks, Chris.

--------------------------------------------------------------------------------

Operator [66]

--------------------------------------------------------------------------------

Your next question comes from the line of Pito Chickering with Deutsche Bank.

--------------------------------------------------------------------------------

Philip Chickering, Deutsche Bank AG, Research Division - Research Analyst [67]

--------------------------------------------------------------------------------

To follow up on Robbie's question on U.S. TAVR. I understand the sales rep issues are holding back growth of new accounts. But are the sales reps really holding back growth in established accounts? Is that where the growth is falling? Is it from the new accounts or from the established accounts?

--------------------------------------------------------------------------------

Michael J. Coyle, Medtronic plc - Executive VP and Group President of Cardiac & Vascular Group [68]

--------------------------------------------------------------------------------

Yes. It's a great question. Actually, what happened was there was a tremendous focus on launching the Evolut PRO+ as well as opening up the NCD accounts. And what we wound up doing because of the relative immaturity of a good bit of our field force is pulling reps who are supporting large accounts to help with that expansion into new accounts.

And obviously, with a new competitor entering the market and some complex messaging having to come in as low-risk patients were approved, it just proved to be too much. We were spreading our field too thin. And so obviously, we've refocused back into those large accounts to make sure that our messaging around improved hemodynamics, the benefits of the Evolut PRO+ in terms of both profile and now adding the pericardial wrap into the large device segment and then, obviously, just selling the benefits of the hemodynamic data that was presented at ACC a year ago. Those are things now that we believe are helping to show this acceleration in growth that I referenced as we head into this quarter versus where we were in January.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [69]

--------------------------------------------------------------------------------

Thanks, Pito.

--------------------------------------------------------------------------------

Operator [70]

--------------------------------------------------------------------------------

Your next question comes from the line of Matthew O'Brien with Piper Sandler.

--------------------------------------------------------------------------------

Matthew Oliver O'Brien, Piper Sandler & Co., Research Division - MD and Senior Research Analyst [71]

--------------------------------------------------------------------------------

I'll just stick with one. Geoff, I appreciate you don't want to say much about this new program that you're going to implement until Investor Day in June, but we've seen contract manufacturers do something like this before, but never really a manufacturing company do something like this. So can you just talk about the potential economic impacts to Medtronic? I mean do you have the scale to kind of work through some of these things on the top line? Is there going to be better pricing so there could be a little bit of gross margin pressure longer term, so there's some free cash flow impacts here? So just how do we think about some of the puts and takes here of this new program?

--------------------------------------------------------------------------------

Geoffrey Straub Martha, Medtronic plc - President & Director [72]

--------------------------------------------------------------------------------

Yes. Well, look, I didn't -- just one clarification on what I spoke about. I think this is the second question around will some of these changes impact our margins. And the answer to that is no, right? We're talking about focus on increasing our revenue and the overall revenue growth as well as the consistency and predictability of that revenue growth, but we don't want to take a step back on the margin improvement that we've built up and the cash flow conversion improvements that we had done over the last couple of years as a result of our -- these are sustainable changes from our Enterprise Excellence Program so we don't want to take a step back on that.

What I mentioned this morning -- on this morning's call was the very specific changes that we want to make to improve orders that are coming in late in the quarter. We have a couple of our larger orders, some of our -- coming in late in the quarter, which stresses our system, and we've got to execute better really to get those in earlier. We're putting too much pressure on the last month, and that's specifically what I spoke of this morning. And when I hinted at for Investor Day was more on what are we doing to realize the full benefits of the pipeline.

Look, like the fundamentals of the business are strong. What I mean by that specifically, you guys know the markets are doing well, we have good market share positions. But more importantly in terms of momentum, the product pipeline is coming to fruition here. So we need to make sure that we put the right programs in place to realize the full benefits of that pipeline around commercial execution. So that's -- we'll get into more of that on Investor Day. What I talked about this morning was more having a regular -- moving some of our back-end loading of our quarter and spreading that more evenly throughout the quarter, but nothing regarding -- nothing changed regarding margin.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [73]

--------------------------------------------------------------------------------

All right. Thanks, Matt.

--------------------------------------------------------------------------------

Operator [74]

--------------------------------------------------------------------------------

Our final question will come from the line of Josh Jennings with Cowen.

--------------------------------------------------------------------------------

Joshua Thomas Jennings, Cowen and Company, LLC, Research Division - MD & Senior Research Analyst [75]

--------------------------------------------------------------------------------

Just 2 questions for Karen on margins. Just on the gross margin pressure you've experienced so far in fiscal '20, can you just help us understand the drivers of that? And is this kind of sub-70% level the new normal? Or is there a recovery path? And has it been FX, pricing pressure, mix shift? And then just on the other income tailwind that you've experienced in fiscal '20 outside of FX hedging, can you talk about the drivers of that benefit and then how sustainable and predictable that line item will be going forward?

--------------------------------------------------------------------------------

Karen L. Parkhill, Medtronic plc - Executive VP & CFO [76]

--------------------------------------------------------------------------------

Yes. Thank you, Josh. No problem. So on gross margins, one of the larger pressures that we've had on gross margin is the increase in China tariff, and as long as those stay, that will be a continued pressure. Gross margin is obviously impacted by mix. And as we introduce some of our key new products, that should help gross margin going forward.

And as we think about the net other expense or income line item, we had a benefit this quarter. That was primarily driven by a swap program that we have in place to hedge the gains and losses that are part of our deferred compensation program and SG& A. And so it was really driven by that. Our SG&A line would have been even better if it didn't have a loss that was effectively offset by a gain in net other.

--------------------------------------------------------------------------------

Ryan Weispfenning, Medtronic plc - VP of IR [77]

--------------------------------------------------------------------------------

Thank you, Josh. Omar, do you want to wrap up?

--------------------------------------------------------------------------------

Omar S. Ishrak, Medtronic plc - Chairman & CEO [78]

--------------------------------------------------------------------------------

Yes. Well, thank you all for your questions. And on behalf of the entire management team, I'd like to thank you again for your continued support and interest in Medtronic.

Look, we'll get this thing right. We've got a task to do here. We'll get acceleration in our growth profile in Q4, and that will continue into FY '21. Our product pipeline is strong, and this team is committed behind it. We couldn't have had -- I couldn't have asked for a better team and more committed. And we'll get this thing right, I assure you.

And then we really look forward to updating you on our progress on our Q4 earnings call. Thank you.

--------------------------------------------------------------------------------

Operator [79]

--------------------------------------------------------------------------------

Ladies and gentlemen, this does conclude today's meeting. Thank you all for joining, and you may now disconnect.

  • Business
    TheStreet.com

    The Average 401(k) Balance by Age

    Average 401(k) Balance by Age Here are the average 401(k) balance by age range as of the second quarter of 2019, according to data released by Fidelity Investments. Ages 20-29 The average 401(k) balance was $11,800 The median 401(k) balance was $4,300 The average contribution rate was 7% of compensation Ages 30-39 The average 401(k) balance was $42,400 The median 401(k) balance was $16,500 The average contribution rate was 7.8% of compensation Ages 40-49 The average 401(k) balance was $102,700 The median 401(k) balance was $36,000 The average contribution rate was 8.5% of compensation Ages 50-59 The average 401(k) balance was $174,100 The median 401(k) balance was $60,900 The average contrib...

  • Business
    TheStreet.com

    The Average Doctor Salary by State and Specialty

    A career as a physician, whether you're a primary care doctor or a specialist, is a noble calling. Doctors adhere to the Hippocratic Oath, which stems from Greek medical history, and calls for physicians to swear to uphold the highest ethical standards in the service of medicine. It depends on what skills a good doctor brings to the table.

  • Investors should prepare for a coronavirus-induced ‘vicious spiral’ more than twice as bad as the financial crisis, says J.P. Morgan
    Business
    MarketWatch

    Investors should prepare for a coronavirus-induced ‘vicious spiral’ more than twice as bad as the financial crisis, says J.P. Morgan

    There is a widespread view on Wall Street that the stock market hit its lowest level of the bear market last month, and that a combination of an ebbing of the coronavirus in late spring and unprecedented fiscal and monetary stimulus will set the stage for a sharp rebound in corporate profits later this year. What's particularly troubling to Matejka is that the current recession has been triggered by a shock to the consumer — which makes up 70% of GDP in Western economies — as workers around the globe are prevented from earning a living by the closures of nonessential business. This dynamic has led J.P. Morgan economists to predict “only a gradual bottoming out in activity, such as seen after the Great Financial Crisis, and not a V-shaped one that we see, for example, after natural disasters.”

  • Business
    U.S.News & World Report

    10 Cheap Dividend Aristocrats to Buy on the Dip

    Investing in a company that pays you no matter how the market performs sounds like exactly what investors need right now, and recent market volatility means that many dividend aristocrats are cheaper than they've been in years. Here are 10 cheap dividend aristocrats to buy -- each one is well-positioned to survive a recession while paying you a healthy dividend. If you're looking for defensive stocks to protect your portfolio, why not turn to the defense industry?

  • Warren Buffett’s Berkshire Hathaway sells off airline stocks, airline industry hit hard by virus
    Business
    Yahoo Finance Video

    Warren Buffett’s Berkshire Hathaway sells off airline stocks, airline industry hit hard by virus

    Warren Buffett's company Berkshire Hathaway sold off millions of dollars in shares from airline companies Delta Air Lines and Southwest Airlines, after the coronavirus pandemic slammed the airline industry. Yahoo Finance's On The Move panel breaks down the latest.

  • Bankers to small businesses: Don't do these things if you want to qualify for SBA loan relief program (PPP)
    Business
    American City Business Journals

    Bankers to small businesses: Don't do these things if you want to qualify for SBA loan relief program (PPP)

    A borrower can ask the SBA to forgive the loan and the interest if workers are not laid off. While community banks account for the majority of the 1,900 lenders that have processed PPP applications, interest from big banks customers are setting new records. Steve Jones, chief executive officer of Dogwood State Bank, one of North Carolina's newest community banks, said the bank has processed about 300 applications since Friday totaling about $80 million for an average of about $267,000 per borrower.

  • Only 9 of the world’s top 100 billionaires have gotten richer during the coronavirus pandemic — and all of them are Chinese
    Business
    MarketWatch

    Only 9 of the world’s top 100 billionaires have gotten richer during the coronavirus pandemic — and all of them are Chinese

    The world's ultrarich are probably not the first financial victims your thoughts go out to as the coronavirus wreaks havoc on the global economy. China's mercurial stock markets help explain this group of outliers. “China has been the relative winner, with its stock markets weathering the virus better than its U.S. and European counterparts,” said Rupert Hoogewerf, Hurun Report chairman and chief researcher.

  • 2 Pros On Disney's Stock: 'Dip Your Toes' And 'Take Your Time'
    Business
    Benzinga

    2 Pros On Disney's Stock: 'Dip Your Toes' And 'Take Your Time'

    Disney's business has evolved over the past five to seven years to the point where it's now heavily diversified, Bapis said. Most recently, the launch of the Disney+ streaming platform gives the company a new direct to consumer business and media distribution strategy. The company's theme parks unit "will hurt" in the near-term due to the coronavirus (COVID-19) pandemic and some level for pain could linger on for up to two years, he said.

  • Recent rally could be a 'bear market trap:' Miller Tabak strategist
    Business
    Yahoo Finance

    Recent rally could be a 'bear market trap:' Miller Tabak strategist

    The recent rallies on the Dow (^DJI) and S&P 500 (^GSPC) have some investors wondering if the worst of the market declines amid the COVID-19 pandemic are over. The Dow, which rose more than 1100 points on Monday, is trading around 20% above its' 52-week intraday low from March. The S&P 500 is up around 16% from its' March 23rd low.

  • Luckin Coffee’s alleged fraud has some silver linings (and even more bad news too)
    Business
    TechCrunch

    Luckin Coffee’s alleged fraud has some silver linings (and even more bad news too)

    Chinese coffee chain super-brand Luckin Coffee has been in the spotlight the past week after the company revealed in an SEC filing that it has undertaken an internal investigation into an alleged $300 million fraud on the part of its former COO. The stock is down another 15% today as investors continue to comprehend the company's disclosure and its positioning in the competitive Chinese coffee market, where the company displaced Starbucks as the retail and delivery leader in just a few short years. On Monday, Goldman Sachs Group Inc. said a group of lenders is putting 76.3 million of Luckin's American depositary shares up for sale, after an entity controlled by Luckin Chairman Charles Zhengyao Lu defaulted on the terms of a $518 million margin loan.

  • Dow Jones Futures Drop, As Coronavirus Stock Market Rally Powers Up; 6 Leaders To Watch Include Amazon, Netflix
    Business
    Investor's Business Daily

    Dow Jones Futures Drop, As Coronavirus Stock Market Rally Powers Up; 6 Leaders To Watch Include Amazon, Netflix

    The Dow Jones futures were sharply lower in Monday evening's trading session, along with S&P 500 futures and Nasdaq futures, after Monday's big coronavirus stock market surge. Top stocks to watch include Dow Jones leaders Apple and Microsoft, FANG stocks Amazon, Facebook and Netflix and Monday's breakout stock Vertex Pharmaceuticals. Dow Jones Futures Today Late Monday, Dow Jones futures traded 0.9% lower vs. fair value, while S&P 500 futures slipped 0.8%.

  • Business
    Barrons.com

    Here Are the Airline Stocks to Buy and the Ones to Avoid, J.P. Morgan Says

    If you're looking for gains in airline stocks, stick with high-quality companies, such as Delta and United, and avoid those with vulnerable balance sheets and operations—namely American and Spirit. Those views come from J.P. Morgan analyst Jamie Baker, who issued a number of ratings changes and price-target cuts in a note published Monday. Baker downgraded (AAL)(ticker: AAL) and (SAVE) (SAVE) from Overweight to Underweight.

  • Carnival Sells 8 Percent Stake to Saudis After Dire Financial Warning
    Business
    Skift

    Carnival Sells 8 Percent Stake to Saudis After Dire Financial Warning

    Carnival Corp. stealthily filed its first quarter earnings on Friday, giving insight into a company on its knees as it faces an unprecedented crisis, and disclosing a long list of risk factors to its business going forward. The world's largest cruise company — which has found itself at the epicenter of the Covid-19 crisis with incidents across its fleet — paused sailings on Mar. 13 after both the U.S. State Department and the Centers for Disease Control advised against cruising. The company's share price has been down 80 percent since the beginning of the year.

  • ‘Rich Dad, Poor Dad’ Robert Kiyosaki: Don’t save your money! Spend it on the ‘best buy for future security’
    Business
    MarketWatch

    ‘Rich Dad, Poor Dad’ Robert Kiyosaki: Don’t save your money! Spend it on the ‘best buy for future security’

    Robert Kiyosaki, the best-selling author of “Rich Dad, Poor Dad,” offered this bit of advice to his 1.3 million followers on Twitter (TWTR)for when that cash finally arrives: Yes, instead of stashing away your check, Kiyosaki says load up on bitcoin (BTCUSD) , gold (GC00)and silver (SI00)in the face of the dying dollar (DXY) . Depends on how much you make This has been a theme on Kiyosaki's social channels for awhile and has taken on an added urgency as the coronavirus pandemic continues to weigh heavily on the stock market: And here's a recent episode on his YouTube channel that's racked up more than half a million views: Gold's been a relatively great place to be over the past three months...

  • Justin Trudeau Says Canada Won't Retaliate Against U.S. for Banning Exports of N95 Masks
    Politics
    Meredith Videos

    Justin Trudeau Says Canada Won't Retaliate Against U.S. for Banning Exports of N95 Masks

    Prime Minister Justin Trudeau said Saturday that Canada won't bring retaliatory or punitive measures against the United States after the Trump administration announced it would prevent the export of N95 protective masks.

  • Jamie Dimon Sees ‘Bad Recession’ and Echoes of 2008 Crisis Ahead
    Business
    Bloomberg

    Jamie Dimon Sees ‘Bad Recession’ and Echoes of 2008 Crisis Ahead

    Jamie Dimon said the coronavirus pandemic will lead to a major economic downturn and stress mirroring the meltdown that nearly brought down the U.S. financial system in 2008. “At a minimum, we assume that it will include a bad recession combined with some kind of financial stress similar to the global financial crisis of 2008,” the chief executive officer of JPMorgan Chase & Co. said Monday in his annual letter to shareholders. At the time, the outbreak still seemed a distant threat, with fewer than 60 cases in the U.S. and none in New York.

  • Business
    Bloomberg

    Billionaire Fertitta Offers Record 15% Loan Rate to Save Empire

    The businessman is offering potential lenders an interest rate of at least 15% to participate in a new $250 million loan for his Golden Nugget casinos and hundreds of restaurants under the Landry's Inc. umbrella that have been ravaged by the coronavirus, according to people with knowledge of the matter. The loan, which matures in October 2023 and is being arranged by Jefferies Financial Group Inc., is one of many levers Fertitta is pulling to shore up liquidity. The pandemic has brought the travel and leisure industry to a near standstill, leaving Fertitta's businesses shuttered and burning cash while tens of thousands of his employees have been furloughed.

  • Coronavirus pandemic scuttles multibillion-dollar merger for Colorado manufacturer
    Business
    American City Business Journals

    Coronavirus pandemic scuttles multibillion-dollar merger for Colorado manufacturer

    A Colorado airplane parts manufacturer called off its multibillion-dollar merger with another company due to the havoc the COVID-19 pandemic is creating in the aviation industry. Woodward Inc. (Nasdaq: WWD), based in Fort Collins, and Hexcel Corp. (NYSE: HXL), based in Stamford, Connecticut, on Monday mutually cancelled their all-stock deal that would have combined major makers of aircraft control systems and parts. Woodward also said Monday that it will reduce spending because of the shrinking demand in aviation manufacturing, including laying off some employees, furloughing others, reducing its CEO's pay by 25% and instituting a hiring and wage freeze.

  • Wells Fargo closes loan window for SBA relief program
    Business
    American City Business Journals

    Wells Fargo closes loan window for SBA relief program

    “Today, the company continues to operate in compliance with an asset cap imposed by its regulator due to actions of past leadership,” Wells Fargo CEO Charlie Scharf said in a statement Sunday. “Since I arrived at the company, I have been clear that we will direct all resources necessary to do the work required by our regulators and we are in the process of doing so,” Scharf said. Wells Fargo closing its loan window under the special SBA program is likely to stun millions of small business owners across the country that bank with Wells Fargo and were planning to apply this week for the SBA PPP loans that eventually become grants if the money is used to keep employees on the payroll and to pay other eligible expenses.

  • Oil prices rebound on hopes for output cut deal
    Business
    AFP

    Oil prices rebound on hopes for output cut deal

    Oil prices rebounded Tuesday on fresh hopes an OPEC-led meeting this week will reach an agreement to reduce oversupply and shore up the market. Prices have fallen sharply since expectations for a quick deal to cut output levels were dashed, but the rescheduling to Thursday of a meeting of major crude producers boosted sentiment. US benchmark West Texas Intermediate was up 3.83 percent to $27.08 a barrel in Asian morning trade.

  • Dow Jones Futures Jump As Virus Cases Slow; Why This Stock Market Rally Is More Dangerous Than The Coronavirus Market Crash
    Business
    Investor's Business Daily

    Dow Jones Futures Jump As Virus Cases Slow; Why This Stock Market Rally Is More Dangerous Than The Coronavirus Market Crash

    Dow Jones futures jumped Monday morning, along with S&P 500 futures and Nasdaq futures as new coronavirus cases slowed in the U.S., Europe and worldwide. Technically, it's a coronavirus stock market rally, but Thursday's follow-through day and Friday's retreat didn't offer much confidence. Apple has fallen below its 200-day moving average.

  • Best Tech Stocks To Buy Or Watch Now: 5 Growth Stocks With Leadership Potential
    Business
    Investor's Business Daily

    Best Tech Stocks To Buy Or Watch Now: 5 Growth Stocks With Leadership Potential

    Some of the best tech stocks to buy or watch now include three stocks in the software sector — Atlassian, DocuSign and Adobe — as well as China e-commerce leader Alibaba and top biotech stock Vertex Pharmaceuticals. The common bond among all five stocks? Bullish relative strength lines and high Composite Ratings from IBD.

  • World
    Financial Times

    Why cruise ship-backed bonds drew $17bn of demand

    It was the deal that sounded like an April Fools' joke: bond investors falling over themselves to give a cruise ship company a boat load of money. Carnival printed the secured bonds as part of a wider $6.25bn rescue financing on April 1. Coronavirus has killed passengers on several of Carnival's cruise ships — incidents that have put the term “floating Petri dishes” firmly in the popular lexicon.

  • Peloton halts live classes as employee tests positive for COVID-19
    Business
    Reuters

    Peloton halts live classes as employee tests positive for COVID-19

    Peloton, whose flagship product is a stationary exercise bike priced at over $2,200, had said on Friday an employee at its New York City-based production studio has tested positive for COVID-19, according to a report https://www.theverge.com/2020/4/3/21207751/peloton-live-classes-employee-tested-positive-covid-19 by The Verge. Peloton said https://blog.onepeloton.com/peloton-covid-19-initiatives on Monday it would continue to add new, pre-recorded content on its Peloton App, which has a monthly subscription cost of $12.99.

  • Clinical trials for potential COVID-19 treatment are now recruiting Bay Area patients
    News
    American City Business Journals

    Clinical trials for potential COVID-19 treatment are now recruiting Bay Area patients

    While there still isn't a drug treatment available on the market for COVID-19, hospitalized patients with moderate to severe symptoms can now turn to an investigational drug being tested in clinical trials nationwide, with several happening right here in the Bay Area. The clinical trials to find out if Gilead's remdesivir is a safe and effective treatment for COVID-19 have recently begun recruiting patients. The drug had previously failed in a clinical trial against the Ebola virus.